Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A*02:01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients

Immunologic Research

Volumn 64, Issue 1, 2016, Pages 171-180

  Sennikov, Sergey Vital’evich ^a   Shevchenko, Julia Alexandrovna ^a   Kurilin, Vasilii Vasil’evich ^a   Khantakova, Julia Nikolaevna ^a   Lopatnikova, Julia Anatol’evna ^a   Gavrilova, Elena Vasil’evna ^c   Maksyutov, Rinat Amirovich ^c   Bakulina, Anastasiya Yur’evna ^d   Sidorov, Sergey Vasil’evich ^b   Khristin, Alexander Alexandrovich ^a   Maksyutov, Amir Zakievich ^c  

^a INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

^b Novosibirsk City Clinical Hospital 1   (Russian Federation)

^c Avaxis Biotherapeutics LLC   (Russian Federation)

^d NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Breast cancer; Cytotoxicity; Dendritic cells; DNA constructs; Transfection

Indexed keywords

DENDRITIC CELL VACCINE; DNA; DNA VACCINE; HLA A ANTIGEN; TUMOR ANTIGEN; CANCER VACCINE; EPITOPE; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; GENE FREQUENCY; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR IMMUNITY; AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL CULTURE; COCULTURE; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; TRANSFECTION;

EID: 84955674084     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8735-0     Document Type: Article

References (28)

1. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011;269(1):64–73.
2. Bei R, Scardino A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. J Biomed Biotechnol. 2010; 102758.
3. Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Cusi MG, Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, Lemonnier FA, Jackson AM, Kosmatopoulos K. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res. 2007;67(14):7028–36.
4. Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Oncology. 2005;68(2–3):163–70.
5. Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther. 2011;19(5):841–53.
6. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91–102.
7. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010;140(6):883–99.
8. Chen KY, Liu J, Ren EC. Structural and functional distinctiveness of HLA-A2 allelic variants. Immunol Res. 2012;53(1–3):182–90.
9. Toes RE, Nussbaum AK, Degermann S, Schirle M, Emmerich NP, Kraft M, Laplace C, Zwinderman A, Dick TP, Müller J, Schönfisch B, Schmid C, Fehling HJ, Stevanovic S, Rammensee HG, Schild H. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med. 2001;194(1):1–12.
10. Peters B, Bulik S, Tampe R, Van Endert PM, Holzhütter HG. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol. 2003;171(4):1741–9.
11. Antonets DV, Maksiutov AZ. TEpredict: software for T-cell epitope prediction. MolBiol (Mosk). 2010;44(1):130–9.
12. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008;36:509–12.
13. Bonini C, Lee SP, Riddell SR, Greenberg PD. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol. 2001;166(8):5250–7.
14. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 2001;19(32):4652–60.
15. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001;17(12):1236–7.
16. Zhang T, Maekawa Y, Hanba J, Dainichi T, Nashed BF, Hisaeda H, Sakai T, Asao T, Himeno K, Good RA, Katunuma N. Lysosomal cathepsin B plays an important role in antigen processing, while cathepsin D is involved in degradation of the invariant chain in ovalbumin-immunized mice. Immunology. 2000;100(1):13–20.
17. Hsieh CS, deRoos P, Honey K, Beers C, Rudensky AY. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol. 2002;168(6):2618–25.
18. Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin Cancer Res. 2005;11(15):5566–71.
19. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol. 2004;340(4):783–95.
20. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med. 1995;182(2):389–400.
21. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol. 2004;172:6649–57.
22. O’Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104(8):2235–46.
23. Rufer N, Brümmendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, Schulzer M, Lansdorp PM. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med. 1999;190(2):157–67.
24. Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA. Perforin: structure, function, and role in human immunopathology. Immunol Rev. 2010;235(1):35–54.
25. Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi R, Barone C. The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol. 2011;2011:894704.
26. Jeras M, Bergant M, Repnik U. In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transpl Immunol. 2005;14:231–44.
27. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383–93.
28. Kulikova EV, Kurilin VV, Shevchenko JA, Obleukhova IA, Khrapov EA, et al. Dendritic cells transfected with a DNA construct encoding tumour-associated antigen epitopes induce a cytotoxic immune response against autologous tumour cells in a culture of mononuclear cells from colorectal cancer patients. Scand J Immunol. 2015;82(2):110–7.